Before visiting, please review our current visitor policies and COVID-19 information.

Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

SWOG S1806

Trial Overview

Official Title

Testing Combined Chemotherapy and Radiation Therapy With and Without the Use of Atezolizumab Immunotherapy in Muscle Invasive Bladder Cancer

Study Purpose

To compare the effects, good and/or bad, of chemotherapy and radiation therapy with or without the use of the immunotherapy drug atezolizumab, used to treat bladder cancer.

Diagnosis

Patient has bladder cancer that has not spread beyond the bladder.

Eligibility

Confirmed Bladder Cancer T2-T4aN0M0

No Prior Chemotherapy for Bladder Cancer

No Prior Radiation

Patients must Sign Approved Informed Consent and Authorization Permitting Release of Personal Health Information

Intervention

  • Group 1: Radiation Therapy, One of the Usual Chemotherapy Regimens
  • Group 2: Radiation Therapy, One of the Usual Chemotherapy Regimens and the Study Drug, Atezolizumab
  • Quality of Life Questionnaires

For more information, visit ClinicalTrials.gov

Key Participation Requirements
Trial Location(s)
Methodist Estabrook Cancer Center Methodist Jennie Edmundson Hospital
Gender
Male or Female
Age
19 years and older
Enrollment Status
Recruiting
Phase
Phase III
Methodist Health System Trial Code
S1806
Related Specialties